Gaithersburg-based Novavax announced preliminary results from the SHIELD-Utah study, conducted with the University of Utah Health, showing that its protein-based COVID-19 vaccine targeting the JN.1 strain caused fewer and less severe reactogenicity symptoms and less disruption to daily activities compared to the Pfizer-BioNTech mRNA vaccine in healthcare workers and first responders. (more…)